DXNVX Launches Genomic Big Data Service... Full-Scale Entry into Medical Data Business

DXVX is launching a genomic big data provision service and officially starting its medical data business.

DXVX announced on the 2nd that it will begin providing anonymized clinical genomic data services to companies and research institutions that require genomic big data, based on the largest genomic analysis database in Korea, consisting of 440,000 cases. In the future, it plans to expand its service sales network to domestic and international new drug developers, pharmaceutical companies, medical institutions, and research organizations.

DXVX offers clinical big data for medical diagnosis classified by various criteria such as age, gender, year, region, and testing methods through its medical information database. The medical information includes clinical analysis data not only for healthy individuals but also for patient groups and various rare diseases, containing extensive genomic information on embryos, amniotic cells, and neonates under one year old in the prenatal and postnatal stages.

Companies or medical institutions that require genomic information or analysis are expected to secure core data for ▲ discovering biomarkers necessary for rare disease and cancer treatment drug development ▲ obtaining data required in the new drug development process ▲ developing personalized treatment methods through results extracted from big data.

Starting with the construction of this genomic big data, DXVX will continuously add genomic big data to discover genetic diseases, oncogenes, and candidate disease biomarkers, while strengthening collaboration with LG CNS and Google Cloud to advance into an AI-based medical data platform.

A DXVX representative stated, “Genomic big data includes extensive genomic information of patient groups beyond general medical information, making it valuable data for new drug development companies that need information on targeted disease groups,” and added, “Starting with this genomic big data service business, we will continuously secure verified medical data and continue to expand collaborations with various global IT companies.”

This content was produced with the assistance of AI translation services.